AIOMEGA® to Present Six Studies on AIO Breathe® Airway Therapy

Showcasing new technologies for adult and pediatric sleep apnea treatment

Apr. 10, 2026 at 1:21pm

Got story updates? Submit your updates here. ›

A minimalist, glowing neon outline depicting the internal structure of the human airway, representing the adaptive and growth-conscious capabilities of the AIO Breathe device.The AIO Breathe device aims to redefine airway therapy by providing a single adaptive platform that can grow with patients from childhood through adulthood.Tyler Today

AIOMEGA®, a medical device company in Texas, announced that its founder Dr. Raghavendra V. Ghuge and co-author Advait R. Ghuge will deliver six peer-reviewed presentations this summer on the AIO Breathe platform. The presentations will highlight the device's ability to remodel the airway through adaptive antero-vertical open airway therapy (AAVOAT), real-time airflow optimization (TAVMLR®), and robotic precision execution of AI-defined algorithms. The AIO Breathe Pediatric (PDS) device is also featured, designed to provide immediate sleep apnea control while supporting craniofacial development in children ages 6-17.

Why it matters

The AIO Breathe platform represents a new paradigm in airway management, offering a single adaptive device that can treat sleep apnea across the lifespan from childhood through adulthood. By combining advanced technologies, the device aims to provide effective, non-surgical treatment options that address both the immediate symptoms of sleep apnea as well as the long-term impacts on growth, development, cognition, and athletic performance in pediatric patients.

The details

The AIO Breathe platform integrates several key technologies to achieve multi-level airway remodeling, including AAVOAT, TAVMLR® real-time airflow optimization, CBCT-based airway analysis, and robotic precision execution of patented algorithms. For pediatric patients ages 6-17, the AIO Breathe Pediatric (PDS) device is designed to provide immediate sleep apnea control while also supporting the natural growth and development of the craniofacial complex. Preliminary clinical observations suggest the pediatric device can improve growth trajectories, behavioral and cognitive function, athletic performance, and overall quality of life.

  • The presentations will be delivered this summer at the AADSM Annual Meeting, AASM SLEEP 2026, and the Southern Sleep Society conference.

The players

Raghavendra V. Ghuge, MD, DABSM, FAASM, MBA

Founder and Chief Medical Officer of AIOMEGA®, the medical device company behind the AIO Breathe platform.

Advait R. Ghuge, BS

Co-author on the presentations and collaborator with Dr. Ghuge at AIOMEGA®.

AIOMEGA®

A medical device innovation company headquartered in Tyler, Texas, specializing in adaptive airway therapy and robotic precision oral appliance technology.

Got photos? Submit your photos here. ›

What they’re saying

“With AIO Breathe, we are establishing a new paradigm — life-long airway management of OSA — a single adaptive platform that grows with the patient from childhood through adulthood.”

— Raghavendra V. Ghuge, MD, DABSM, FAASM, MBA, Founder and Chief Medical Officer, AIOMEGA®

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

The AIO Breathe platform represents a significant advancement in sleep apnea treatment, offering an integrated solution that can address the condition across the lifespan. By combining cutting-edge technologies, the device aims to provide effective, non-surgical options that not only control symptoms but also support long-term growth, development, and overall health and well-being.